Why Is LYCIA THERAPEUTICS I (LYCA) Stock Up Today?
By the Top Tier Newswire AI Desk · November 18, 2026 at 12:14 AM ET · reviewed against 11 wire stories
LYCIA THERAPEUTICS I (LYCA) is up +8.07% in the latest session. Our newswire has captured 11 stories on LYCA across 4 sources in the last 36 hours, with AI sentiment reading bullish (avg 64/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Lycia Therapeutics (LYCA) shares rose 8.07% to close at $30.92. The primary driver for the move was a wave of new analyst coverage, with four firms initiating positive ratings on the stock within the last 36 hours.
What Happened
Jefferies initiated coverage on Lycia Therapeutics with an Outperform rating and a price target of $50. Guggenheim also started coverage with a Buy rating, citing the potential of the food allergy market. TD Cowen initiated the stock with a Buy rating, and LifeSci Capital began coverage with an Outperform rating. This cluster of positive initiations occurred as the company prepared to present at the 2026 Jefferies Global Healthcare Conference.
What The Data Shows
The stock printed eight fresh 52-week highs on November 17, 2026. Over the last eight sessions, the share price moved up 1.4%, rising from $30.50 to the current level of $30.92. The company currently has a market capitalization of $1.8 billion, with a 52-week trading range of $22.19 to $36.49. Insider activity has been exclusively positive over the last 90 days, with three buys totaling $38.5 million and no sells. The most recent transaction was recorded on November 4, 2026. Venrock Healthcare Capital Partners III, L.P., a 10% holder, executed purchases on November 2, October 28, and October 23, 2026.
What To Watch
Investors will monitor the company’s presentation at the 2026 Jefferies Global Healthcare Conference for further updates on its pipeline and commercial strategy.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
LYCA · Nov 18 session (5-min) · +1.39% vs prior close · updated 8:53 PM ETAI sentiment, last 36h · averaged over 11 stories · 64/100 bullish
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
3d agoInvesting.com MarketsBULLISH 72General
Why is Lycia Therapeutics stock surging today?
Why is Lycia Therapeutics stock surging today?
3d agoGuruFocusBULLISH 61Analyst
LYCA Initiated by Jefferies -- Price Target Announced at $50
3d agoThe FlyBULLISH 63Analyst
Lycia Therapeutics initiated with an Outperform at LifeSci Capital
3d agoThe FlyBULLISH 64Analyst
Guggenheim starts Lycia Therapeutics with a Buy on food allergy market potential
3d agoThe FlyBULLISH 63Analyst
Lycia Therapeutics initiated with a Buy at Guggenheim
3d agoInvesting.com Analyst RatingsBULLISH 63Analyst
Guggenheim initiates Lycia Therapeutics stock with buy rating
Guggenheim initiates Lycia Therapeutics stock with buy rating
3d agoThe FlyBULLISH 63Analyst
Lycia Therapeutics initiated with a Buy at TD Cowen
3d agoThe FlyBULLISH 63Analyst
Lycia Therapeutics initiated with a Buy at Jefferies
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →